Abstract:

Objective To investigate the efficacy and safety of capecitabine combined with recombinant human endostatin（Endostar） in the treatment of patients with advanced colon cancer after stent implantation. Methods A total of 79 patients with advanced colon cancer who were unable to undergo surgical resection and complicated with intestinal obstruction were recruited between  January 2010 and January 2017. Patients  were  divided into  control group（n=40）that received capecitabine  alone or treatment  group（n=39） that received capecitabine with Endostar. The short-term efficacy and adverse reactions were compared between the two groups，and the progression-free survival and overall survival were observed. Results All patients were successfully implanted with intestinal stents to remove the obstruction and completed the chemotherapies. The total response rate of the treatment group was higher than that in the control group（46.15% vs 30.00%），but there was no significant difference（χ²=2.921，P=0.087），and the treatment group showed significantly higher disease control rate than that in the control group（69.23% vs 50.00%，χ²=3.978，P=0.046）. The incidence rate of adverse reactions associated with chemotherapy and intestinal stenting was similar between the two groups（P＞0.05）. Median progression-free survival was 16 months in the treatment  group，significantly longer than 13 months in the control group（P<0.05）. Similarly，median overall survival was 25 months in the treatment group，significantly longer than 19 months in the control group（P<0.05）. Conclusions Intestinal stenting can effectively relieve intestinal obstruction in patients with colon cancer，and capecitabine combined with Endostar is superior to capecitabine alone.

Key words: Colon neoplasms, Stent, Intestinal obstruction, Capecitabine, Endostar, Efficacy